SOURCE: Oxford Biomedica Plc

October 19, 2005 02:01 ET


OXFORD, UK -- (MARKET WIRE) -- October 19, 2005 --

FOR IMMEDIATE RELEASE                                     19 OCTOBER 2005


Oxford, UK: 19 October 2005 - Oxford BioMedica (LSE: OXB), a leading gene
therapy company, today announced that the Company's licensee Wyeth
Pharmaceuticals presented preclinical efficacy data with its 5T4
antibody-targeted therapy for the treatment of solid tumours at the 10th 
World Congress on Advances in Oncology and 8th International Symposium on 
Molecular Medicine in Crete, Greece on 13-15 October 2005.

The presentation was made by Dr. Erwin Boghaert of Wyeth Research. It 
included preclinical data showing that the targeted therapy is cytotoxic 
against tumour cells expressing the antigen, 5T4; and that the product 
inhibited tumour growth in in vitro models of various human 5T4-
expressing cancers. In one preclinical model of lung cancer, 100% of mice 
treated with the 5T4-targeted immunoconjugate survived through an 
observation period of 150 days, whereas those treated with vehicle or a 
nonbinding immunoconjugate had a median survival of 40 to 60 days. In 
this presentation, the unique characteristics of the 5T4 tumour antigen 
were highlighted, including its broad expression on most solid tumours 
throughout the evolution of disease. Wyeth concluded that the above 
preclinical evidence supports clinical evaluation of the 5T4-targeted 
The presentation was titled "Tumour Targeted Chemotherapy with 
Calicheamicin Immunoconjugates" and was presented during a session on 
Clinical and Molecular Oncology. The 10th World Congress on Advances in 
Oncology and 8th International Symposium on Molecular Medicine is a joint 
conference organised by the Medical School University of Crete and three 
leading oncology journals: International Journal of Oncology, Oncology 
Reports and International Journal of Molecular Medicine.

The 5T4 antibody-targeted cancer therapy is being developed by Wyeth
Pharmaceuticals, which licensed rights to Oxford BioMedica's antibody 
against the tumour antigen 5T4. Wyeth has used Oxford BioMedica's agent 
to develop an antibody-conjugate based on its expertise with the anti-
cancer agent calicheamicin. The license agreement with Wyeth is valued at 
$24 million in upfront and milestone payments, plus royalties on product 
sales. Like Oxford BioMedica's novel cancer immunotherapy, TroVax(R), the
5T4 antibody-targeted cancer therapy could, in principle, be used to 
treat a wide range of cancers and could, therefore, command a substantial 

Oxford BioMedica's Chief Executive, Professor Alan Kingsman, said: "The
preclinical data generated by Wyeth with this targeted chemotherapy 
approach using Oxford BioMedica's anti-5T4 antibody are very promising. 
The presentation also highlights the unique profile of our 5T4 tumour 
antigen as a target for anti-cancer approaches. We are delighted by 
Wyeth's progress and look forward to the initiation of clinical 
development with the product."


For further information, please contact:
Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive        Tel: +44 (0)1865 783 000

City/Financial Enquiries:
Buchanan Communications
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson    Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:
Northbank Communications
Sue Charles/ Katja Stout/ Ashley Lilly          Tel: +44 (0)20 7886 8150

Notes to editors:

1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising 
in the development of novel gene-based therapeutics with a focus on the 
areas of oncology and neurotherapy. The Company was established in 1995 
as a spin out from Oxford University, and is listed on the London Stock 

Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, 
and a preclinical targeted antibody therapy in collaboration with Wyeth. 
In neurotherapy, the Company's lead product is a gene therapy for 
Parkinson's disease, which is expected to enter clinical trials in 2006, 
and four further preclinical candidates. The Company is underpinned by 
over 80 patent families, which represent one of the broadest patent 
estates in the field.

The Company has a staff of approximately 70 split between its main 
facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in 
San Diego, California. Oxford BioMedica has corporate collaborations with 
Wyeth, Intervet, Viragen, MolMed and Kiadis; and has licensed technology 
to a number of companies including Merck & Co, Biogen Idec and Pfizer.

Further information is available at

2. 5T4 Antibody-Targeted Therapy
The 5T4 antibody-targeted therapy is composed of a recombinant humanised
anti-5T4 antibody conjugated with a cytotoxic anti-tumour antibiotic,
calicheamicin. The antibody binds specifically to the tumour antigen 5T4, 
which is expressed on the surface of a wide range of solid tumours 
throughout the evolution of disease. Binding of the anti-5T4 antibody 
portion of the conjugate with the 5T4 antigen results in the formation of 
a complex that is internalised. Upon internalisation, a calicheamicin 
derivative is released, which causes cell death. Wyeth has successfully 
demonstrated the concept of antibody-targeted chemotherapy through the 
development and registration of its product  Mylotarg(R), which targets 
the CD33 antigen present on myeloid leukaemia cells.

                  This information is provided by RNS
        The company news service from the London Stock Exchange